UPDATED: Bluebird joins the layoff flock to reality as gene therapy biotech sheds staff to save itself - Endpoints News

Bluebird bio is laying off about 30% of its workforce to save itself before the FDA decides the fate of two of its gene therapies in August and September and plans to file for a third approval in the first quarter of next year. The dire situation came into cl…

Blue­bird bio is lay­ing off about 30% of its work­force to save it­self be­fore the FDA de­cides the fate of two of its gene ther­a­pies in Au­gust and Sep­tem­ber and plans to file for a third ap­p… [+3788 chars]

full article...